Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.63 |
| ▸ | FAP | Q12884 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355114 | 1.00 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL297708 | 1.00 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16710010 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16578291 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6824150 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6824148 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL27616477 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL6923872 | 0.89 | DPP4 (0.67) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3628073 | 0.84 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5966905 | 0.84 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1784220-B | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG | 2011-08-03 | — | — | CN | claimed |
| CN-101837127-A | The application of glutaminyl and glutamate cyclase effector | PROBIODRUG AG | 2010-09-22 | — | — | CN | claimed |
| CN-101365476-A | Combination of a DPP-IV inhibitor and a gastrin compound | WARATAH PHARMACEUTICALS INC (CA) | 2009-02-11 | — | — | CN | claimed |
| CN-1321682-C | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2007-06-20 | — | — | CN | claimed |
| CN-1582149-A | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROBIODRUG AG (DE) | 2005-02-16 | — | — | CN | claimed |
| CN-1443068-A | Combinations of depepotidyl peptidase IV inhibitors and other antidiabetic agents for treatment of diabete mellitus | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | CN | claimed |
| CN-1420797-A | Methods for improving islet signaling in diabetes and for its prevention | PROBIODRUG GES FUER ARZNEIM (DE) | 2003-05-28 | — | — | CN | claimed |
| CN-101932321-B | Combination therapy comprising an SGLT inhibitor and a DPP4 inhibitor | MITSUBISHI TANABE PHARMA CORP. (JP) | 2016-05-18 | — | — | CN | disclosed |
| CN-101267838-B | Use of DPP-IV inhibitors to reduce hypoglycemic events | NOVARTIS AG | 2012-09-05 | — | — | CN | disclosed |
| CN-102302781-A | Medical use of inhibitors of glutaminyl and glutamate cyclases | PROBIODRUG AG | 2012-01-04 | — | — | CN | disclosed |
| CN-101618216-B | Direct compression formulation and process | NOVARTIS AG | 2012-01-04 | — | — | CN | disclosed |
| CN-101277688-B | Formulation comprising metformin and vildagli ptin | NOVARTIS AG (CH) | 2011-12-14 | — | — | CN | disclosed |
| CN-101035522-B | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin | NOVARTIS AG (CH) | 2011-12-07 | — | — | CN | disclosed |
| CN-1655786-A | Combination of a DPP IV inhibitor and a cardiovascular compound | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| US-6911467-B2 | Antidiabetic agents | FERRING BV (NL) | 2005-06-28 | — | — | US | disclosed |
| CN-1582149-A | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROBIODRUG AG (DE) | 2005-02-16 | — | — | CN | disclosed |
| EP-1351932-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | Ferring BV (NL) | 2003-10-15 | — | — | EP | disclosed |
| CN-1420797-A | Methods for improving islet signaling in diabetes and for its prevention | PROBIODRUG GES FUER ARZNEIM (DE) | 2003-05-28 | — | — | CN | disclosed |
| US-20030096857-A1 | Novel antidiabetic agents | FERRING BV (NL) | 2003-05-22 | — | — | US | disclosed |
| WO-2001040180-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096857-A1 | Novel antidiabetic agents | DPP4, SLC5A2, SLC2A4 | DPP4 1/4885DPP8 44/4885DPP9 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.